Symbicort Turbuhaler (Lyfjaver) Noregur Innöndunarduft 160/4,5 míkróg/skammt Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

symbicort turbuhaler (lyfjaver) noregur innöndunarduft 160/4,5 míkróg/skammt

lyfjaver ehf. - budesonidum inn; formoterolum inn fúmarat - innöndunarduft - 160/4,5 míkróg/skammt

Seroquel Prolong Forðatafla 50 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 50 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 50 mg

Seroquel Prolong Forðatafla 300 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 300 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 300 mg

Seroquel Prolong Forðatafla 200 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 200 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 200 mg

Seroquel Prolong Forðatafla 150 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 150 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 150 mg

Candpress Comp Tafla 16 mg/12,5 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

candpress comp tafla 16 mg/12,5 mg

teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg

Valpress Comp Filmuhúðuð tafla 160/12,5 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 160/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg

Valpress Comp Filmuhúðuð tafla 80/12,5 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 80/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg

Kanuma Euroopa Liit - islandi - EMA (European Medicines Agency)

kanuma

alexion europe sas - sebelipasa alfa - lipid efnaskipti, innfelldar villur - Önnur meltingarvegi og efnaskipti vörur, - kanuma er ætlað til langtímameðferð með ensímuppbótarmeðferð (ert) hjá sjúklingum á öllum aldri, með skort á lysósölt sýru lípasa (lal).

Ultomiris Euroopa Liit - islandi - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - blóðrauði, ofsakláði - valdar ónæmisbælandi lyf - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.